Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Mohamed-Elmoctar Neine"'
1
Akademický článek
Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
Autor: Natalia Hawken, Saku Torvinen, Mohamed-Elmoctar Neine, Ikbel Amri, Mondher Toumi, Samuel Aballéa, Adam Plich, Nicolas Roche
Publikováno v: BMC Pulmonary Medicine, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background Dry powder inhalers (DPIs) are often used in asthma and chronic obstructive pulmonary disease (COPD) therapies. Using the discrete choice experiment (DCE) methodology, this study conducted in France was designed to assess patients
Externí odkaz: https://doaj.org/article/da4977ec11b448969f99c40ae37f2240
Zobrazit plný text záznamu
2
Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
Autor: NA Hawken, Samuel Aballéa, Ikbel Amri, Saku Torvinen, Nicolas Roche, Mondher Toumi, Mohamed-Elmoctar Neine, Adam Plich
Publikováno v: BMC Pulmonary Medicine, Vol 17, Iss 1, Pp 1-11 (2017)
BMC Pulmonary Medicine
Background Dry powder inhalers (DPIs) are often used in asthma and chronic obstructive pulmonary disease (COPD) therapies. Using the discrete choice experiment (DCE) methodology, this study conducted in France was designed to assess patients’ prefe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3481c001f5e210aaff51f313fbabcc8b
http://link.springer.com/article/10.1186/s12890-017-0439-x
Zobrazit plný text záznamu
3
Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom
Autor: Mohamed-Elmoctar Neine, Jameel Nazir, Isaac Odeyemi, Samuel Aballéa, K. Maman, Zalmai Hakimi, B. Briquet, Andy Garnham
Publikováno v: Value in Health. 18:783-790
Background Mirabegron, a first-in-class selective oral β 3 -adrenoceptor agonist, has similar efficacy to most antimuscarinic agents and a lower incidence of dry mouth in patients with overactive bladder (OAB). Objectives To evaluate the cost-effect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e50b51cafe65742d60c731aea8282c
https://doi.org/10.1016/j.jval.2015.05.011
Zobrazit plný text záznamu
8
Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison
Autor: Jameel Nazir, Samuel Aballéa, Emad Siddiqui, Isaac Odeyemi, Katia Desroziers, K. Maman, Zalmai Hakimi, Mohamed-Elmoctar Neine
Publikováno v: European Urology. 65:755-765
Context Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as first-line pharmacologic therapy. Mirabegron is a first-in-class β3-adrenoceptor agonist licensed for the treatment of OAB and has shown to be well tolerated and eff
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b59bdf0c4cefe6703a1a23f1629d4e6
https://doi.org/10.1016/j.eururo.2013.11.010
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje